{"id":"NCT00380367","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Safety, Tolerability and Immunogenicity of HPV (Human Papilloma Virus) Vaccine in Healthy Females 9 to 15 Years of Age in India (V501-029)","officialTitle":"Evaluation of Safety, Tolerability and Immunogenicity of Quadrivalent HPV Vaccine in Healthy Females 9 to 15 Years of Age in India","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2007-05-03","primaryCompletion":"2008-02-04","completion":"2008-02-04","firstPosted":"2006-09-26","resultsPosted":"2009-04-14","lastUpdate":"2023-05-31"},"enrollment":110,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"PREVENTION"},"conditions":["Papillomavirus Infections"],"interventions":[{"type":"BIOLOGICAL","name":"Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine","otherNames":[]}],"arms":[{"label":"Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)","type":"EXPERIMENTAL"}],"summary":"The purpose of this study is to evaluate the safety and tolerability of the Quadrivalent Human Papilloma Virus (HPV) vaccine in healthy females 9 to 15 years of age in India. Quadrivalent HPV Vaccine is composed of L1 virus-like particles (VLPs) from HPV types 6, 11, 16, and 18.","primaryOutcome":{"measure":"Percentage of Participants Who Seroconvert to Each HPV Serotype (Types 6, 11, 16, 18) at Month 7","timeFrame":"One month post-dose 3 (Month 7)","effectByArm":[{"arm":"Quadrivalent HPV VLP Vaccine (Types 6, 11, 16, 18)","deltaMin":96.97,"sd":null}],"pValues":[]},"eligibility":{"minAge":"9 Years","sex":"FEMALE","healthyVolunteers":true,"inclusionCount":3,"exclusionCount":6},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["35997582"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":0,"n":108},"commonTop":["Injection site pain","Pyrexia","Injection site tenderness","Injection site erythema","Injection site swelling"]}}